Canaccord Genuity raises Intersect ENT [XENT]’s rating to Buy and price target to $25

DPRO Stock

Canaccord Genuity took its Intersect ENT [XENT] rating to the equivalent of Buy from Hold, and the price target to $25.0 from $18, in a research note dated 2021-01-11. That figure represents around a 10.72% premium from where the company’s shares closed on Friday. Other analysts also revised their coverage, with JP Morgan’s analysts downgrading […]